Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.
| Revenue (Most Recent Fiscal Year) | $9.04M |
| Net Income (Most Recent Fiscal Year) | $-292.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 68.80 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1687.08% |
| Net Margin (Trailing 12 Months) | -1687.08% |
| Return on Equity (Trailing 12 Months) | -76.10% |
| Return on Assets (Trailing 12 Months) | -65.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 87.04M |
| Free Float | 80.35M |
| Market Capitalization | $866.10M |
| Average Volume (Last 20 Days) | 0.65M |
| Beta (Past 60 Months) | 1.93 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.69% |
| Percentage Held By Institutions (Latest 13F Reports) | 44.58% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |